Plasma Cell Targeting for Rapid Chronic Fatigue Syndrome Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic fatigue syndrome (CFS) lack effective compounds that provide rapid symptom relief without the lag period associated with B-cell depleting agents like Rituximab, and are not suitable for patients who do not respond to existing therapies.
Innovation Solution
Administering inhibitory or cytotoxic agents specifically targeting plasma cells, such as proteasome inhibitors like Bortezomib, or monoclonal antibodies like Daratumumab, to induce apoptosis and reduce autoantibody production in plasma cells, combined with B-cell depleting agents like Rituximab, to achieve immediate symptom relief and long-lasting suppression of plasma cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If B-cell depleting agents like Rituximab are administered to treat CFS, then plasma cell suppression is achieved, but symptom relief is delayed
Solution Approach 1:
The treatment approach is segmented into two distinct components: B-cell depleting agents (like Rituximab) for long-term plasma cell suppression, and plasma cell cytotoxic agents (like bortezomib or daratumumab) for rapid symptom relief. This segmentation allows each agent to target its specific function optimally without compromising the other.
Solution Approach 2:
Plasma cell cytotoxic agents are administered preliminarily to achieve rapid symptom relief within weeks, before the longer-acting B-cell depleting agents take full effect. This preliminary action addresses the immediate symptom relief need while the sustained suppression mechanism is established.
2Reliability
If existing CFS treatments are used, then some patients may respond, but they are not suitable for patients who do not respond to existing therapies
Solution Approach 1:
The combined treatment regimen serves multiple patient populations: it works for patients who partially respond to B-cell depleting agents alone, for those who need rapid symptom relief, and for patients with varying disease severities. The dual-mechanism approach makes the treatment universally applicable across diverse CFS patient profiles.
Solution Approach 2:
The treatment parameters are adjusted by combining two different mechanisms of action with different time courses. The rapid-acting plasma cell cytotoxic agent changes the temporal parameter of symptom relief, while the B-cell depleting agent maintains sustained suppression, creating a flexible treatment that can be adapted to individual patient needs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides rapid symptom relief for CFS patients within weeks, overcoming the delay seen with Rituximab, and effectively targets autoantibody-producing plasma cells, offering sustained benefit for a subset of patients.
Implementation Method 1
proteasome inhibitors like Bortezomib
Implementation Method 2
to induce apoptosis and reduce autoantibody production in plasma cells
Implementation Method 3
monoclonal antibodies like Daratumumab
Implementation Method 4
inhibitory or cytotoxic agent against plasma cells
Implementation Method 5
B-cell depleting agents like Rituximab
Implementation Method 6
to achieve immediate symptom relief and long-lasting suppression of plasma cells
Data Source
AI summary
The present disclosure relates in a first aspect to a method for the treatment of chronic fatigue syndrome (CFS) comprising administering to a patient in need thereof a therapeutically effective amount of inhibitory or cytotoxic agent against plasma cells. In a further aspect, the present disclosure relates to a combination of the inhibitory or cytotoxic agent against plasma cells with a B-cell depleting agent or an inhibitor of B-cell activation in the treatment of chronic fatigue syndrome. In addition, a combination of an inhibitory or cytotoxic agent against plasma cells and B-Cell depleting agent or an inhibitor of B-cell activation are described. Said combination may be provided in form of a kit comprising suitably effective dosages of said compounds. Further, the use of the compounds or the combination in the treatment of CFS is described.